Decreased survival in patients treated by chemotherapy after targeted therapy compared to immunotherapy in metastatic melanoma

BACKGROUND: Cytotoxic chemotherapy (CC) is currently used in metastatic melanoma after patients have developed resistance to immune checkpoint inhibitors (ICI) and/or Mitogen‐Activated Protein Kinase inhibitors (MAPKi). We sought to evaluate if a previous treatment by ICI or MAPKi influences clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Mangin, Marie‐Alix, Boespflug, Amélie, Maucort Boulch, Delphine, Vacheron, Charles‐Hervé, Carpentier, Isabelle, Thomas, Luc, Dalle, Stéphane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124115/
https://www.ncbi.nlm.nih.gov/pubmed/33932099
http://dx.doi.org/10.1002/cam4.3760

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124115/
https://www.ncbi.nlm.nih.gov/pubmed/33932099
http://dx.doi.org/10.1002/cam4.3760

Ejemplares similares